Announcements Trials
Browse Landscape

Phase

Phase 2 44Phase 1 20Phase 3 12Phase 1/2 9Phase NA 4Phase 4 3Phase EARLY_PHASE1 2Phase 2/3 2

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Non-Small Cell Lung Cancer Metastatic 1

Interventions

Letrozole 20Docetaxel 16Cyclophosphamide 13Zoledronic Acid 12exemestane 11Trastuzumab 11Anastrozole 11Paclitaxel 10Tamoxifen 9Capecitabine 9Fulvestrant 8Epirubicin 8pegfilgrastim 7pertuzumab 6liposomal doxorubicin 6abemaciclib 6Saline Solution 6palbociclib 5Sodium Chloride 5Dexmedetomidine 5Carboplatin 5Bupivacaine 5Bevacizumab 5ribociclib 4pegylated granulocyte colony-stimulating factor 4eribulin 4Tranexamic Acid 4Standard of Care 4Pamidronate 4Filgrastim 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Breast Neoplasms × Taxes × Clear all
NCT05420454 2022-07-01

A Study for the Neoadjuvant Treatment of Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 4 Recruiting
1,576 enrolled
Breast

Breast Neoplasms

NCT05420467 2022-07-01

A Study for the Adjuvant Treatment of Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 4 Recruiting
2,413 enrolled
Breast

Breast Neoplasms

NCT04031885 2021-08-24

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Eli Lilly and Company

Phase 4 Terminated
4 enrolled 9 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡